Ultrashort acting hypnotic barbiturates
The subject invention concerns novel compounds that are useful as ultrashort acting hypnotic barbiturates. Specifically exemplified are derivatives of barbituric and thiobarbituric acids. They are rapidly metabolized by blood and tissue enzymes to form polar metabolites with no hypnotic activity and which are rapidly eliminated.
1. A compound selected from the group consisting of:
3-methyl-4,6-dioxo-5-phenylhexahydropyrimidine-5-acetic Acid, Adamantanemethyl Ester
3-methyl-4,6-dioxo-5-phenylhexahydropyrimidine-5-acetic Acid, Cyclohexyl Ester
3-methyl-4,6-dioxo-5-δ 2 -cyclopentylhexahydropyrimidine-5-acetic Acid Adamantanemethyl Ester
3-methyl-4,6-dioxo-5-δ 2 -cyclopentylhexahydropyrimidine-5-acetic Acid Cyclohexyl Ester
and pharmaceutically acceptable salts thereof.
2. A compound selected from the group consisting of:
3-methyl-4,6-dioxo-5-phenylhexahydropyrimidine-5-acetic Acid, Neopentyl Ester
3-methyl-4,6-dioxo-5-phenylhexahydropyrimidine-5-acetic Acid Isobutyl Ester
3-methyl-4,6-dioxo-5-δ 2 -cyclopentylhexahydropyrimidine-5-acetic Acid Neopentyl Ester
3-methyl-4,6-dioxo-5-δ 2 -cyclopentylhexahydropyrimidine-5-acetic Acid Isobutyl Ester
and pharmaceutically acceptable salts thereof.
3. A compound selected from the group consisting of:
4,6-dioxo-5-allyl-5-isopentylhexahydropyrimidine-3-aceticacid, Ethyl Ester
3-ethoxycarbonyl-4,6-dioxo-5-allyl-5-isopentylhexahydropyrimidine
and pharmaceutically acceptable salts thereof.
4. A composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.
5. A composition comprising the compound according to claim 2 and a pharmaceutically acceptable carrier or diluent.
6. A composition comprising the compound according to claim 3 and a pharmaceutically acceptable carrier or diluent.